SIRPA and cancer: By testing cells of either an adrenergic or mesenchymal phenotype, the two divergent cellular phenotypes responsible for a large part of the tumor heterogeneity found in neuroblastoma, we further characterized the involvement of CD47-SIRPα checkpoint in this cancer type.